166
Participants
Start Date
September 30, 2025
Primary Completion Date
June 17, 2030
Study Completion Date
June 17, 2032
mRNA-2808
intravenous
NOT_YET_RECRUITING
Tisch Cancer Institute at Mount Sinai, New York
NOT_YET_RECRUITING
Memorial Sloan-Kettering Cancer Center, New York
NOT_YET_RECRUITING
Penn Medicine, Philadelphia
NOT_YET_RECRUITING
Atrium Health Levine Cancer Institute, Charlotte
NOT_YET_RECRUITING
Emory University Hospital, Atlanta
NOT_YET_RECRUITING
University of Alabama at Birmingham Hospital, Birmingham
RECRUITING
Sarah Cannon Research Institute, Nashville
NOT_YET_RECRUITING
The Medical College of Wisconsin, Milwaukee
NOT_YET_RECRUITING
UCSF, San Francisco
NOT_YET_RECRUITING
Mass General Brigham, Boston
ModernaTX, Inc.
INDUSTRY